Directory
Diego Arango Del Corro

Diego Arango Del Corro

Degree: PhD


darango(ELIMINAR)@irblleida.cat

ResearcherID: http://www.researcherid.com/rid/M-5667-2016

Publications

  • Dopeso, H; Rodrigues, P; Cartón-García, F; Macaya, I; Bilic, J; Anguita, E; Jing, L; Brotons, B; Vivancos, N; Beà, L; Sánchez-Martín, M; Landolfi, S; Hernandez-Losa, J; Cajal, SRY; Nieto, R; Vicario, M; Farre, R; Schwartz, S Jr; van Ijzendoorn, SCD; Kobayashi, K; Martinez-Barriocanal, A; Arango, D

    RhoA downregulation in the murine intestinal epithelium results in chronic Wnt activation and increased tumorigenesis

    iScience 27 109400-109400. .

    [doi:10.1016/j.isci.2024.109400]

  • Matos, AI; Peres, C; Carreira, B; Moura, LIF; Acurcio, RC; Vogel, T; Wegener, E; Ribeiro, F; Afonso, MB; Santos, FMF; Martínez-Barriocanal, A; Arango, D; Viana, AS; Góis, PMP; Silva, LC; Rodrigues, CMP; Graca, L; Jordan, R; Satchi-Fainaro, R; Florindo, HF

    Polyoxazoline-Based Nanovaccine Synergizes with Tumor-Associated Macrophage Targeting and Anti-PD-1 Immunotherapy against Solid Tumors

    Advanced Science 10 -. .

    [doi:10.1002/advs.202300299]

  • González-Callejo P; Gener P; Díaz-Riascos ZV; Conti S; Cámara-Sánchez P; Riera R; Mancilla S; García-Gabilondo M; Peg V; Arango D; Rosell A; Labernadie A; Trepat X; Albertazzi L; Schwartz S Jr; Seras-Franzoso J; Abasolo I

    Extracellular vesicles secreted by triple negative breast cancer stem cells trigger pre-metastatic niche remodeling and metastatic growth in the lungs.

    INTERNATIONAL JOURNAL OF CANCER 152 2153-2165. .

    [doi:10.1002/ijc.34447]

  • Rafael D; Guerrero M; Marican A; Arango D; Sarmento B; Ferrer R; Durán-Lara EF; Clark SJ; Schwartz S Jr

    Delivery Systems in Ocular Retinopathies: The Promising Future of Intravitreal Hydrogels as Sustained-Release Scaffolds.

    Pharmaceutics 15 -. .

    [doi:10.3390/pharmaceutics15051484]

  • Tögel L; Nightingale R; Wu R; Chüeh AC; Al-Obaidi S; Luk I; Dávalos-Salas M; Chionh F; Murone C; Buchanan DD; Chatterton Z; Sieber OM; Arango D; Tebbutt NC; Williams D; Dhillon AS; Mariadason JM

    Author Correction: DUSP5 is methylated in CIMP-high colorectal cancer but is not a major regulator of intestinal cell proliferation and tumorigenesis.

    SCIENTIFIC REPORTS 13 2422-2422. .

    [doi:10.1038/s41598-023-29328-y]

  • Carton-Garcia, F; Brotons, B; Anguita, E; Dopeso, H; Tarragona, J; Nieto, R; Garcia-Vidal, E; Macaya, I; Zagyva, Z; Dalmau, M; Sanchez-Martin, M; van Ijzendoorn SCD; Landolfi, S; Hernandez-Losa, J; Schwartz S Jr; Matias-Guiu, X; Ramón Y Cajal S; Martinez-Barriocanal, A; Arango, D

    Myosin Vb as a tumor suppressor gene in intestinal cancer.

    ONCOGENE 41 5279-5288. .

    [doi:10.1038/s41388-022-02508-2]

  • Luk IY; Jenkins LJ; Schoffer KL; Ng I; Tse JWT; Mouradov D; Kaczmarczyk S; Nightingale R; Burrows AD; Anderson RL; Arango D; Dopeso H; Croft L; Richardson MF; Sieber OM; Liao Y; Mooi JK; Vukelic N; Reehorst CM; Afshar-Sterle S; Whitehall VLJ; Fennell L; Abud HE; Tebbutt NC; Phillips WA; Williams DS; Shi W; Mielke LA; Ernst M; Dhillon AS; Clemons NJ; Mariadason JM

    Epithelial de-differentiation triggered by co-ordinate epigenetic inactivation of the EHF and CDX1 transcription factors drives colorectal cancer progression.

    CELL DEATH AND DIFFERENTIATION 29 2288-2302. .

    [doi:10.1038/s41418-022-01016-w]

  • Fourniols, T; Maggio, V; Rafael, D; Colaco, A; García Vidal E; Lopes, A; Schwartz, S; Martinez-Barriocanal, A; Preat, V; Arango, D

    Colorectal cancer inhibition by BET inhibitor JQ1 is MYC-independent and not improved by nanoencapsulation.

    EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS 171 39-49. .

    [doi:10.1016/j.ejpb.2021.10.017]

  • Giralt, I; Gallo-Oller, G; Navarro, N; Zarzosa, P; Pons, G; Magdaleno, A; Segura, MF; Sabado, C; Hladun, R; Arango, D; Sánchez de Toledo J; Moreno, L; Gallego, S; Roma, J

    Dickkopf-1 Inhibition Reactivates Wnt/ß-Catenin Signaling in Rhabdomyosarcoma, Induces Myogenic Markers In Vitro and Impairs Tumor Cell Survival In Vivo.

    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES 22 -. .

    [doi:10.3390/ijms222312921]

  • Bazzocco S; Dopeso H; Martínez-Barriocanal Á; Anguita E; Nieto R; Li J; García-Vidal E; Maggio V; Rodrigues P; de Marcondes PG; Schwartz S Jr; Aaltonen LA; Sánchez A; Mariadason JM; Arango D

    Identification of ZBTB18 as a novel colorectal tumor suppressor gene through genome-wide promoter hypermethylation analysis.

    Clinical Epigenetics 13 88-88. .

    [doi:10.1186/s13148-021-01070-0]

  • Andrade F; Rafael D; Vilar-Hernández M; Montero S; Martínez-Trucharte F; Seras-Franzoso J; Díaz-Riascos ZV; Boullosa A; García-Aranda N; Cámara-Sánchez P; Arango D; Nestor M; Abasolo I; Sarmento B; Schwartz S

    Polymeric micelles targeted against CD44v6 receptor increase niclosamide efficacy against colorectal cancer stem cells and reduce circulating tumor cells in vivo.

    JOURNAL OF CONTROLLED RELEASE 331 198-212. .

    [doi:10.1016/j.jconrel.2021.01.022]

  • Overeem AW; Li Q; Qiu YL; Carton-Garciá F; Leng C; Klappe K; Dronkers J; Hsiao NH; Wang JS; Arango D; van IJzendoorn SCD

    A molecular mechanism underlying genotype-specific intrahepatic cholestasis resulting from MYO5B mutations.

    Hepatology 72 213-229. .

    [doi:10.1002/hep.31002]

Projects

  • CHEMBAR: Chemopreventive effects of barley-based foods rich
  • Towards precision radiotherapy for rectal cancer patients Principal Investigator
  • Contratos predoctorales de formación en investigación en salud (PFIS)
  • Nueva aproximación terapéutica para el cáncer colorectal.
  • EPH Receptor Signaling in Endometrial Cancer
  • Antioxidant treatment as a novel therapeutic option for microvillus inclusion disease. ARMED
  • Programa d'Impuls al Talent i l'Ocupabilitat (2021-2024)
  • Nueva estrategia terapéutica para ael cáncer gástrico basada en la modulación de la señalización de RHOA
  • Desarrollo de nanosistemas de marcaje de CXCR4 mediante radiosondas para la imagen molecular de células tumorales y del microambiente tumoral
  • Identificación de nuevos biomarcadores de respuesta a los compuestos regorafenib y TAS-102 en pacientes con cáncer colorrectal.
  • Targeting tumor microevironment by a translational multivalent nanomedicine: towards an effective anticancer combination immunotherapy